Headlines about Nevro Corp (NYSE:NVRO) have been trending somewhat negative this week, AlphaOne Sentiment reports. The research firm, a division of Accern, rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Nevro Corp earned a daily sentiment score of -0.11 on AlphaOne’s scale. AlphaOne also gave news headlines about the medical equipment provider an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an impact on the company’s share price in the next several days.

Nevro Corp (NYSE:NVRO) traded down 2.83% during mid-day trading on Friday, hitting $85.22. The stock had a trading volume of 640,345 shares. The firm’s market cap is $2.49 billion. Nevro Corp has a 12-month low of $61.52 and a 12-month high of $106.93. The company has a 50-day moving average of $91.81 and a 200-day moving average of $88.25.

Nevro Corp (NYSE:NVRO) last announced its earnings results on Thursday, February 23rd. The medical equipment provider reported ($0.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by $0.14. Nevro Corp had a negative return on equity of 14.57% and a negative net margin of 18.91%. The firm had revenue of $70.50 million for the quarter, compared to the consensus estimate of $66.41 million. During the same period in the previous year, the firm earned ($0.51) EPS. Nevro Corp’s revenue for the quarter was up 113.0% on a year-over-year basis. Analysts expect that Nevro Corp will post ($0.54) earnings per share for the current year.

Several research analysts recently commented on the company. Canaccord Genuity assumed coverage on Nevro Corp in a research note on Thursday, March 23rd. They set a “buy” rating and a $120.00 target price for the company. B. Riley reaffirmed a “buy” rating and set a $108.00 price objective on shares of Nevro Corp in a research report on Wednesday, March 1st. Leerink Swann upped their price objective on Nevro Corp from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Friday, February 24th. Northland Securities reaffirmed a “positive” rating and set a $110.00 price objective on shares of Nevro Corp in a research report on Thursday, February 2nd. Finally, Zacks Investment Research cut Nevro Corp from a “buy” rating to a “hold” rating in a research report on Wednesday, January 4th. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $103.18.

ILLEGAL ACTIVITY NOTICE: This story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.thecerbatgem.com/2017/04/21/nevro-corp-nvro-receiving-somewhat-negative-press-coverage-analysis-shows.html.

In related news, Director Wilfred E. Jaeger sold 43,980 shares of the business’s stock in a transaction that occurred on Friday, March 3rd. The stock was sold at an average price of $95.03, for a total transaction of $4,179,419.40. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Michael Enxing sold 38,500 shares of the business’s stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $91.01, for a total value of $3,503,885.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 136,180 shares of company stock worth $12,730,657. 12.10% of the stock is owned by corporate insiders.

Nevro Corp Company Profile

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

5 Day Chart for NYSE:NVRO

Receive News & Stock Ratings for Nevro Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp and related stocks with our FREE daily email newsletter.